The study began in February 2004, with its primary completion and estimated completion dates not specified. The last update was submitted on June 30, 2025. These dates are crucial as they indicate the ...

The intervention tested is the Medtronic AT500, a device designed to prevent and terminate AT episodes in patients with conventional pacemaker needs. This device is intended to improve patient ...

Medtronic's growth strategies, dividend stability, and innovation focus amidst debt concerns and market risks. Click here to ...

The uptick in the historic period can be linked to an increased preference for home-based cardiac monitoring, an enhancement in the number of cardiac surgeries and implantations, a burgeoning demand ...

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter ...

The first-ever pacemaker to include Managed Ventricular Pacing (MVP®), the EnRhythm™ Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary ...

Her relapse into depression felt like defeat—but it offered vital clues to achieving lasting psychiatric relief. The ...

The global medical devices market size is calculated at USD 586.2 billion in 2025 and is expected to reach around USD ...

Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...

NEW YORK CITY -- Operators acknowledged the complex electrophysiological concerns around transcatheter tricuspid valve ...

The Simplici-T Annuloplasty System offers a first-of-its-kind approach to mitral and tricuspid valve repair. It is the first flexible band to eliminate the need for traditional sizing, providing a ...